Patents Assigned to MG Pharma Inc.
-
Publication number: 20180360899Abstract: An object of the present invention is to provide a novel agent for maintaining healthy obesity. The present invention relates to agent for maintaining healthy obesity containing processed Glycyrrhizae radix and/or Angelica keiskei as an active ingredient.Type: ApplicationFiled: December 2, 2016Publication date: December 20, 2018Applicant: MG PHARMA INC.Inventors: Shigetoshi OKUMURA, Yuka SASAKAWA
-
Patent number: 8691949Abstract: The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or treat diseases caused by hyperglycemia, in particular, diabetes and diabetic complications (a composition for preventing or treating diseases caused by hyperglycemia, an antidiabetic), based on the above-mentioned effect. A feature of the present invention is using a peptide consisting of the amino acid sequence of Leu-Ser-Glu-Leu as an active ingredient.Type: GrantFiled: October 28, 2009Date of Patent: April 8, 2014Assignee: MG Pharma Inc.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Chunning Tong, Yuka Sasakawa
-
Patent number: 8394769Abstract: The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6).Type: GrantFiled: August 7, 2008Date of Patent: March 12, 2013Assignee: MG Pharma Inc.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Hiroaki Fujino, Junnei Hidasa
-
Patent number: 8357776Abstract: The present invention provides a composition (composition for suppressing re-elevation of cholesterol) that has the effects of suppressing re-elevation of cholesterol in patients with high cholesterol or pre-high cholesterol, and that can therefore be used to suppress re-elevation of cholesterol in those patients. The present invention also provides a composition which, due to the effects described above, can be used to prevent or treat conditions or diseases caused by high cholesterol due to cholesterol re-elevation, specifically hypercholesterolemia, arteriosclerosis and diseases and conditions stemming therefrom. The composition of this invention uses as an active component an edible protein hydrolysate, preferably a globin proteolysate or a peptide consisting of Val-Val-Tyr-Pro.Type: GrantFiled: November 17, 2006Date of Patent: January 22, 2013Assignee: MG Pharma Inc.Inventors: Kyoichi Kagawa, Chizuko Fukuhama
-
Publication number: 20110201551Abstract: The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or treat diseases caused by hyperglycemia, in particular, diabetes and diabetic complications (a composition for preventing or treating diseases caused by hyperglycemia, an antidiabetic), based on the above-mentioned effect. A feature of the present invention is using a peptide consisting of the amino acid sequence of Leu-Ser-Glu-Leu as an active ingredient.Type: ApplicationFiled: October 28, 2009Publication date: August 18, 2011Applicant: MG PHARMA INC.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Chunning Tong, Yuka Sasakawa
-
Publication number: 20110166073Abstract: The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6).Type: ApplicationFiled: August 7, 2008Publication date: July 7, 2011Applicant: MG PHARMA INC.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Hiroaki Fujino, Junnei Hidasa
-
Publication number: 20090155376Abstract: The present invention provides compositions (blood sugar increase inhibitors) that have an action of lowering the blood sugar level of a subject in a hyperglycemic condition and are for use in lowering the blood sugar level of such a subject. Moreover, the present invention provides compositions for use in preventing or treating diseases resulting from hyperglycemia, in particular, diabetes and diabetic complications, due to the aforementioned action (a preventive or ameliorative composition for diseases resulting from hyperglycemia, an antidiabetic agent).Type: ApplicationFiled: November 15, 2005Publication date: June 18, 2009Applicant: MG PHARMA INC.Inventors: Kyoichi Kagawa, Toshihiko Naruse, Chizuko Fukuhama
-
Publication number: 20070191282Abstract: The present invention provides a composition (composition for suppressing re-elevation of cholesterol) that has the effects of suppressing re-elevation of cholesterol in patients with high cholesterol or pre-high cholesterol, and that can therefore be used to suppress re-elevation of cholesterol in those patients. The present invention also provides a composition which, due to the effects described above, can be used to prevent or treat conditions or diseases caused by high cholesterol due to cholesterol re-elevation, specifically hypercholesterolemia, arteriosclerosis and diseases and conditions stemming therefrom. The composition of this invention uses as an active component an edible protein hydrolysate, preferably a globin proteolysate or a peptide consisting of Val-Val-Tyr-Pro.Type: ApplicationFiled: November 17, 2006Publication date: August 16, 2007Applicant: MG PHARMA INC.Inventors: Kyoichi Kagawa, Chizuko Fukuhama